Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.42 |
| ▸ | CCND3 | P30281 | 13/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.42 |
| ▸ | CDK2 | P24941 | 12/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.40 |
| ▸ | CDK1 | P06493 | 8/20 | 0.40 |
| ▸ | CDK7 | P50613 | 8/20 | 0.40 |
| ▸ | CDK9 | P50750 | 8/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291660 | 0.84 | CDK4 (0.44) | CDK4CCND3CDK6CDK2CCNA2 | |
| SCHEMBL20038535 | 0.83 | HRH3 (0.33) | CDK4CCND3CDK6CDK2CCNA2 | |
| SCHEMBL20038383 | 0.82 | LMNA (0.34) | CDK4CCND3CDK6CDK2CCNA2 | |
| SCHEMBL20037477 | 0.81 | PDCD1 (0.47) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL20249391 | 0.81 | CDK4 (0.42) | CDK4CCND3CDK6CDK2CCNA2 | |
| SCHEMBL20203553 | 0.81 | CDK4 (0.48) | CDK4CCND3CDK6CDK2CCNA2 | |
| SCHEMBL18291526 | 0.81 | CDK4 (0.40) | CDK4CCND3CDK6CDK2CDK1 | |
| SCHEMBL21414338 | 0.78 | CDK4 (0.42) | CDK4CCND3CDK6CDK2CCNA2 | |
| SCHEMBL20356369 | 0.76 | CDK4 (0.41) | CDK4CCND3CDK6CDK2CCNA2 | |
| SCHEMBL21985979 | 0.76 | CYP2C9 (0.47) | KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CDK4 1/4885CCND3 44/4885CDK6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.